Pharma Seeks Creative Staffing Solutions Amid Economic Uncertainty
This article was originally published in The Pink Sheet Daily
Executive Summary
While the industry does need more staff, it is reluctant to take the risk of hiring permanent full-time employees.
You may also be interested in...
In R&D Shakeup, Pfizer Tries New Outsourcing Model
Contract research organizations Icon and Parexel will become Pfizer's primary clinical trail service providers under the new partnerships.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.